Neuroimaging MAO-B in Medication Free TR-MDD Using Novel Tracer

Major Depressive Disorder Clinical Trial

— DETB  

Official title:

Neuroimaging MAO-B in Medication Free and Treatment Resistant Major Depressive Disorder Using Novel MAO-B Tracer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02153281
• Other study ID #: DETB-071-13
• Status: Completed
• Phase: N/A
• Start date: June 2014
• Est. completion date: May 2019

Study information

• Verified date: May 2019
• Source: Centre for Addiction and Mental Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if monoamine oxidase B (MAO-B) total distribution volume (VT), after phenelzine treatment and if so to what extent.

Description:

Subjects will receive a PET and MRI scan before and after treatment with phenelzine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: May 2019
• Est. primary completion date: May 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• 18-80 years of age

• good physical health

• Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of current major depressive episode (MDE)

• DSM-IV diagnosis of major depressive disorder (MDD) verified by SCID for DSM-IV and a psychiatric consultation

• greater than 17 on the 17 item HDRS (Hamilton Depression Rating Scale).

• history of non-response to several different antidepressant classes

Exclusion Criteria:

• herbal, drug or medication use (that affect CNS function)

• suicide attempts

• drug or medication use within eight weeks (+5 half lives of medication)

• history of substance abuse or any neurotoxin use

• history of psychotic symptoms

• history of central nervous system (CNS) medical illness

• current substance abuse

• test positive on pregnancy test (for women)

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Other:
• phenelzine treatment
Subjects will have a PET and MRI scan before and after treatment with phenelzine.

Locations

Country	Name	City	State
Canada	Center for Addiction and Mental Health	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Centre for Addiction and Mental Health

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MAO-B VT levels measured with PET in MDE secondary to MDD		8 weeks

External Links

•   Information about research at the Centre for Addiction and Mental Health